All In Biotech

Drug Trial Radar · NCT05155020

A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Feb 11, 2022

Primary completion

Aug 5, 2022

Study completion Aug 5, 2022

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Dec 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.

Conditions

  • Asthma

Interventions

  • AK120Biological

    AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.

  • AK120Biological

    AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

  • AK120Biological

    AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.

  • PlaceboBiological

    Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.Time frame: At week 12

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Jingmei General Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Baogang Hospital, Inner Mongolia, China

    Baotou, Inner Mongolia, China

  • Inner Mongolia People's Hospital

    Hohhot, Inner Mongolia, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Jiangxi Provincial Prople's Hospita

    Nanchang, Jiangxi, China

  • Jiangxi Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Jilin Province People's Hospital

    Changchun, Jilin, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine,

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.